ATOSSA THERAPEUTICS, INC. Income Statement
ATOS|5 years of annual SEC 10-K data (FY2012-FY2016)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
ATOSSA THERAPEUTICS, INC. reported $1,758 in revenue and $16M in net loss for FY2016. Revenue has grown at a 4.0% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -15.14 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|
| Revenue | $1.8K | $40.1K | $632.6K | $481.8K | $1.5K |
| Cost of Revenue | $132.4K | $0 | $345.5K | $35.7K | $5.2K |
| Gross Profit | -$130.7K | $40.1K | $137.1K | $416.2K | -$95.7K |
| SG&A Expense | $8.8M | $8.1M | $8.6M | $3.0M | $3.2M |
| R&D Expense | $2.4M | $1.1M | $1.1M | $2.0M | - |
| Operating Income | -$12.8M | -$12.2M | -$10.8M | -$5.1M | -$3.4M |
| Interest Expense | - | - | $360 | $12.0K | $18.0K |
| Income Tax | - | $0 | $0 | $0 | $0 |
| Net Income | -$15.8M | -$14.7M | -$10.8M | -$122.9K | -$122.9K |
| EPS (Diluted) | -$8.31 | -$0.61 | -$0.70 | -$0.41 | -$0.38 |
| Shares Outstanding | 2.2M | 24.6M | 18.6M | 12.9M | 11.3M |
| Gross Margin | -7431.9% | 100.0% | 21.7% | 86.4% | -6379.3% |
| Operating Margin | -725746.2% | -30323.0% | -1704.9% | -1052.0% | -228612.7% |
| Profit Margin | -896491.6% | -36518.8% | -1704.9% | -25.5% | -8190.5% |